SEC Form 4 · accession 0001358403-18-000027
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edmund Harrigan
Director
Period of report
Feb 20, 2018
Accepted (ET)
Feb 22, 2018 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.91 | Feb 20, 2018 | A | 20,000 | A | — | Feb 19, 2028 | Common Stock | 20,000 | 20,000 | D |
| Stock Option (right to buy)F2 | $6.91 | Feb 20, 2018 | A | 3,166 | A | — | Feb 19, 2028 | Common Stock | 3,166 | 23,166 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 36 equal monthly installments from the date of grant, and will vest in full upon a change in control.
- F2The stock option vests and becomes exercisable in equal installments on each of March 20, April 20, May 20, and June 14, 2018, and will vest in full upon a change in control.